Feb 22–25, 2027 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
James E Crowe, Jr., Lisa Purcell, and Jonah Rainey
-
Scientific Organizers: James E Crowe, Jr., Lisa Purcell, and Jonah Rainey
James E Crowe, Jr., MD
Vanderbilt University Medical Center
Lisa Purcell, PhD
Third Rock Ventures
Jonah Rainey
Lilly
Important Deadlines
Meeting Summary
Joint Meeting
This meeting runs jointly with Computational Drug Discovery: Tools Across the Translational Pipeline.
About This Meeting:
To mark 40 years since the approval of the first monoclonal antibody for therapeutic use, this conference will highlight the major advances that have accompanied the field. While innovation continues with traditional formats, these large molecules now encompass conjugates, multiple targets, target selectivity, and de novo design alongside combinations and innovative dosing paradigms. These innovations have afforded antibodies unparalleled success in combatting rare disease for a few patients to deployment to millions in record time during the recent pandemic.
This Keystone Symposia conference on Antibodies as Drugs: Evolving Design, Formats and Approaches will expose attendees to the most cutting-edge technologies employed in antibody development. Each session will build and expand on the last, allowing for deep interrogation of the innovations across indications and platforms. Sessions will delve into multispecific antibodies and the use of combinations or engagement of specific targets for specific indications, selectively active antibodies and novel platforms for conditional engagement, exogenous targets and advancements in pathogens, and novel scaffolds including other formats and antibody-like molecules.
This conference will bring together the innovators across different modalities to share the major strides gained and apply these advances to new clinical indications for patients. Joint programming with Computational Drug Discovery: Tools Across the Translational Pipeline includes a session for attendees to hear from pioneers in the field to explore how computational approaches to antibody design can be applied across these modalities.
By showcasing the innovations that have established antibodies as transformative therapeutics, this meeting positions itself as a unique forum for advancing the next generation of antibody-based approaches and shaping the future of biologic drug development.
Check out the speaker highlights in the video below:
Unique Career Development Opportunities
This meeting will feature a Career Roundtable where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities. Find out more about Career Roundtables here: https://www.keystonesymposia.org/diversity/career-development-initiatives
SPECIAL RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR SPONSOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
KEYSTONE SYMPOSIA THANKS OUR MEETING EXHIBITOR(S):
KEYSTONE SYMPOSIA THANKS THESE DONOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
THESE COMPANIES HAVE GENEROUSLY AGREED TO COVER THE EXPENSES OF THEIR EMPLOYEES WHO ARE SPEAKING AT THIS MEETING:
GRANT RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS
Subscribe for Updates